PDF factsheet

HDL increasing drugs in cardiovascular prevention for all type of patients, clinical trials results

anacetrapib versus placebo
DEFINE, 2010 NCT00685776	anacetrapib 100mg fr 18 months versus placebo	patients with coronary heart disease or at high risk for coronary heart disease	double-blind 20 countries
REVEAL HPS-3 TIMI-55, 2017 NCT01252953	anacetrapib 100mg daily versus placebo	high risk patients already taking statins	double-blind Follow-up duration: median 4 years
REALIZE, 2015 NCT01524289	oral anacetrapib 100 mg for 52 weeks versus placebo	patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 2·59 mmol/L or higher without cardiovascular disease or 1·81 mmol/L or higher with cardiovascular disease	double-blind Follow-up duration: 52 weeks
bezafibrate versus placebo
BECAIT, 1996	bezafibrate 200 mg three times daily versus placebo	dyslipidaemic male survivors of myocardial infarction who were younger than 45 years at the time of the event	double blind Follow-up duration: 5.0 years Sweden
BIP, 2000	bezafibrate 400 mg/d versus placebo	patients with a previous myocardial infarction or stable angina, total cholesterol of 180 to 250 mg/dL, HDL-C < or =45 mg/dL, triglycerides < or =300 mg/dL, and low-density lipoprotein cholesterol < or =180 mg/dL	double blind Follow-up duration: 6.2 y Israel
LEADER, 2002	bezafibrate 400 mg daily versus placebo	men with lower extremity arterial disease	double-blind Follow-up duration: 4.6y UK
SENDCAP, 1998	bezafibrate 400 mg daily versus placebo	type 2 diabetic subjects without a history of clinical cardiovascular	double blind Follow-up duration: 3.0 years UK
clofibrate versus placebo
Acheson, 1972	clofibrate versus placebo	cerebral vascular disease	NA Follow-up duration: 6 years UK
Begg, 1971	clofibrate versus placebo	peripheral arteriopathy	Follow-up duration: 3.5 y
CDP Clofibrate, 1975	clofibrate 1.8 mg/d versus placebo	men, 30-64 y	double blind Follow-up duration: 6.2 years USA
Cullen, 1974	clofibrate versus placebo		Follow-up duration: 2 years
Hanefeld, 1991	clofibric acid 1.6 g/day versus placebo	newly diagnosed middle-aged (30- to 55-yr-old) patients with non-insulin-dependent diabetes mellitus	double-blind Follow-up duration: 5 years Germany
Harrold, 1969	clofibrate versus placebo	diabetic retinopathy	double-blind Follow-up duration: 1 years
Newcastle, 1971	clofibrate 1.5-2 g daily versus placebo	Hommes et femmes < 65 ans	double blind Follow-up duration: 3.6 y UK
Scottish, 1971	clofibrate 1.6-2 g daily versus placebo	Hommes et femmes, de 40 à 69 ans	double blind Follow-up duration: 3.4 years Scotland
VA Neurology Section, 1974	clofibrate versus placebo	treatment of cerebrovascular disease	Follow-up duration: 1.8 years USA
WHO clofibrate, 1978	clofibrate 1.6 g daily versus olive oil	primary prevention, Hommes, de 30 à 59 ans	double blind Follow-up duration: 5.3 years Scotland, Hungary, Czech Republic
dalcetrapib versus placebo
dal-VESSEL, 2011	dalcetrapib 600 mg daily versus placebo	men and women with coronary heart disease or coronary heart disease risk equivalents with HDL-cholesterol levels <50 mg/dL	double-blind Follow-up duration: 12 weeks
dal-OUTCOMES, 2012 NCT00658515	dalcetrapib 600 mg daily beginning 4 to 12 weeks after an index ACS event versus placebo	patients with recent acute coronary syndrome	double-blind Follow-up duration: 31 montsh (median) 27 countries
etofibrate versus placebo
Emmerich, 2009	etofibrate 1g/j versus placebo	patients with type 2 diabetes mellitus and concomitant diabetic retinopathy	double-blind Follow-up duration: 12 months Germany
evacetrapib versus placebo
ACCELERATE, 2017 NCT01687998	evacetrapib at adose of 130 mg versus placebo	Patients at a High-Risk for Vascular Outcomes who had at least one of the following conditions: an acutecoronary syndrome within the previous 30 to 365 days, cerebrovascular atheroscleroticdisease, peripheral vascular arterial disease, or diabetes mellitus with coronaryartery disease	double-blind 37 countries
fenofibrate versus placebo
DAIS, 2001	fenofibrate 200 mg/day versus placebo	men and women with type 2 diabetes and coronary atherosclerosis	double-blind Follow-up duration: 3.3 years Canada, Finland, France, Sweden
FIELD, 2005 ISRCTN64783481	fenofibrate 200mg/d versus Placebo	participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry	double blind Follow-up duration: 5 years Australia, New Zealand, Finland
fenofibrate versus placebo (on top simvastatine)
ACCORD lipid, 2010 NCT00000620	fenofibrate on top simvastatin versus placebo (on top simvastatine)	high-risk patients with type 2 diabetes	double-blind Follow-up duration: 4.7y United States and Canada
gemfibrozil versus placebo
Helsinki (HHS), 1987	gemfibrozil 1,2 g/d versus placebo	asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5.2 mmol per liter]	double blind Follow-up duration: 5 years Finland
HHS (Frick)(secondary prev subgroup), 1993	gemfibrozil 600 mg twice daily versus placebo	individuals who exhibited symptoms and signs of possible coronary heart disease	double blind Follow-up duration: 5.0 years Sweden
LOCAT, 1997	gemfibrozil 1200 mg/d versus placebo	post-coronary bypass men, who had an HDL cholesterol concentration < or = 1.1 mmol/L and LDL cholesterol < or = 4.5 mmol/L	double blind Follow-up duration: 32 months Germany
VA-HIT, 1999 NCT00283335	gemfibrozil 1.2g daily versus placebo	men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less	double blind Follow-up duration: 5.1 years USA
niacin versus control
VA drugs, 1968	niacin versus		double blind Follow-up duration: 3.2 years
niacin versus ezetimibe
ARBITER 6-HALTS (niacin vs ezetimibe), 2009 NCT00397657	extended-release niacin 1 g/d, titrated to max tolerable dose up to 2 g/d (HDL-focused strategy) versus ezetimibe 10 mg/d (LDL-focused strategy)	patients with known coronary or vascular disease or coronary risk equivalents	open Follow-up duration: 14 months US
niacin versus placebo
CDP niacin, 1975	niacin 3 mg/d versus placebo	Hommes, de 30 à 64 ans	double blind Follow-up duration: 6.2 years
niacin versus placebo (on top statin)
AIM-HIGH, 2011 NCT00120289	high-dose, extended-release niacin in gradually increasing doses up to 2000 mg daily (+ simvastatin) versus placebo	patients with a history of cardiovascular disease, high triglycerides, and low levels of HDL cholesterol	double blind Follow-up duration: 32 months US, Canada
HPS 2-Thrive, NCT00461630	2 g of extended-release niacin and 40 mg of laropiprant versus placebo	patients with vascular disease	double blind Follow-up duration: 3.9y (median) UK, Scandinavia, China
Oxford Niaspan Study, 2009 NCT00232531	niacin 2g daily (added to statin therapy) versus placebo (statins alone)	patients with low HDL-C (<40 mg/dl) and either a type 2 diabetes with coronary heart disease or a carotid/peripheral atherosclerosis	double blind Follow-up duration: 1 year USA
ARBITER 2, 2009	long-acting niacin target dose of 1 g/day (added to statin therapy) versus placebo	patients with known coronary artery disease and well controlled on statin therapy	double blind Follow-up duration: 1 y USA
HATS, 2001	simvastatin plus niacin versus placebo	patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels	double blind Follow-up duration: 3 y USA, Canada
torcetrapib versus placebo
RADIANCE 1, 2007 NCT00136981	atorvastatin combined with 60 mg of torcetrapib versus atorvastatin monotherapy	patients with heterozygous familial hypercholesterolemia	open Follow-up duration: 24 months
ILLUMINATE, 2007 NCT00134264	torcetrapib 60mg daily plus atorvastatin (at a dose established during the runinperiod) versus atorvastatin alone	patients at highcardiovascular risk	double blind Follow-up duration: 1.52y 7 countries
RADIANCE 2, 2007	torcetrapib 60mg daily (on top of atorvastatin attitrated dose) versus placebo +atorvastatin attitrated dose	patients with mixed dyslipidaemia	double blind Follow-up duration: 24 months North America and Europe
ILLUSTRATE, 2007 NCT00134173	atorvastatin plus 60 mg of torcetrapib daily versus atorvastatin monotherapy	patients with coronary disease	open Follow-up duration: 24 months North America and Europe

Options

Group by
in first

in second

Order trials by

Filter

display ongoing trials

Type of trial

Limit to tags

Exclude tags